Daily telemonitoring of exhaled nitric oxide and symptoms in the treatment of childhood asthma

Johan C. de Jongste, Silvia Carraro, Wim C. Hop, Eugenio Baraldi, Henk Jan Aanstoot, Attillio Boner, Fernando Maria de Benedictis, Sander W W Feith, Marquita H. Greijn, Linda Landi, Gianluigi Marseglia, Elio Novembre, Lydia Pescollderung, Giovanni Rossi, Ruud Schornagel, Anja A P H Vaessen-Verberne, Leonieke N. van Veen

Research output: Contribution to journalArticle

156 Citations (Scopus)

Abstract

Rationale: Asthma treatment might improve when inhaled steroids are titrated on airway inflammation. Fractional exhaled nitric oxide (FE NO0.05), a marker of eosinophilic airway inflammation, can be measured at home. Objectives: We assessed daily FENO0.05 telemonitoring in the management of childhood asthma. Methods: Children with atopic asthma (n = 151) were randomly assigned to two groups: FE NO0.05 plus symptom monitoring, or monitoring of symptoms only. All patients scored asthma symptoms in an electronic diary over 30 weeks; 77 received a portable nitric oxide (NO) analyzer. Data were transmitted daily to the coordinating centers. Patients were phoned every 3 weeks and their steroid dose was adapted according to FENO0.05 and symptoms, or according to symptoms. Children were seen at 3, 12, 21, and 30 weeks for examination and lung function testing. The primary end point was the proportion of symptom-free days in the last 12 study weeks. Measurements and Main Results: Telemonitoring was feasible with reliable FENO0.05 data for 86% of days, and valid diary entries for 79% of days. Both groups showed an increase in symptom-free days, improvement of FEV1 and quality of life, and a reduction in steroid dose. None of the changes from baseline differed between groups. The difference in symptom-free days over the last 12 weekswas0.3% (P = 0.95; 95% confidence interval, -10 to 11%). There was a trend for fewer exacerbations in the FE NO0.05 group. Conclusions: Thirty weeks of daily FENO0.05 and symptom telemonitoring was associated with improved asthma control and a lower steroid dose. We found no added value of daily FENO0.05 monitoring compared with daily symptom monitoring only.

Original languageEnglish
Pages (from-to)93-97
Number of pages5
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume179
Issue number2
DOIs
Publication statusPublished - Jan 15 2009

Fingerprint

Nitric Oxide
Asthma
Steroids
Inflammation
Therapeutics
Quality of Life
Confidence Intervals
Lung

Keywords

  • Airway inflammation
  • Inhaled corticosteroid
  • Lung function
  • Symptom-free days
  • Telemedicine

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Cite this

de Jongste, J. C., Carraro, S., Hop, W. C., Baraldi, E., Aanstoot, H. J., Boner, A., ... van Veen, L. N. (2009). Daily telemonitoring of exhaled nitric oxide and symptoms in the treatment of childhood asthma. American Journal of Respiratory and Critical Care Medicine, 179(2), 93-97. https://doi.org/10.1164/rccm.200807-1010OC

Daily telemonitoring of exhaled nitric oxide and symptoms in the treatment of childhood asthma. / de Jongste, Johan C.; Carraro, Silvia; Hop, Wim C.; Baraldi, Eugenio; Aanstoot, Henk Jan; Boner, Attillio; de Benedictis, Fernando Maria; Feith, Sander W W; Greijn, Marquita H.; Landi, Linda; Marseglia, Gianluigi; Novembre, Elio; Pescollderung, Lydia; Rossi, Giovanni; Schornagel, Ruud; Vaessen-Verberne, Anja A P H; van Veen, Leonieke N.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 179, No. 2, 15.01.2009, p. 93-97.

Research output: Contribution to journalArticle

de Jongste, JC, Carraro, S, Hop, WC, Baraldi, E, Aanstoot, HJ, Boner, A, de Benedictis, FM, Feith, SWW, Greijn, MH, Landi, L, Marseglia, G, Novembre, E, Pescollderung, L, Rossi, G, Schornagel, R, Vaessen-Verberne, AAPH & van Veen, LN 2009, 'Daily telemonitoring of exhaled nitric oxide and symptoms in the treatment of childhood asthma', American Journal of Respiratory and Critical Care Medicine, vol. 179, no. 2, pp. 93-97. https://doi.org/10.1164/rccm.200807-1010OC
de Jongste, Johan C. ; Carraro, Silvia ; Hop, Wim C. ; Baraldi, Eugenio ; Aanstoot, Henk Jan ; Boner, Attillio ; de Benedictis, Fernando Maria ; Feith, Sander W W ; Greijn, Marquita H. ; Landi, Linda ; Marseglia, Gianluigi ; Novembre, Elio ; Pescollderung, Lydia ; Rossi, Giovanni ; Schornagel, Ruud ; Vaessen-Verberne, Anja A P H ; van Veen, Leonieke N. / Daily telemonitoring of exhaled nitric oxide and symptoms in the treatment of childhood asthma. In: American Journal of Respiratory and Critical Care Medicine. 2009 ; Vol. 179, No. 2. pp. 93-97.
@article{7239f4bab5ee4a2987f5c7ece33ed711,
title = "Daily telemonitoring of exhaled nitric oxide and symptoms in the treatment of childhood asthma",
abstract = "Rationale: Asthma treatment might improve when inhaled steroids are titrated on airway inflammation. Fractional exhaled nitric oxide (FE NO0.05), a marker of eosinophilic airway inflammation, can be measured at home. Objectives: We assessed daily FENO0.05 telemonitoring in the management of childhood asthma. Methods: Children with atopic asthma (n = 151) were randomly assigned to two groups: FE NO0.05 plus symptom monitoring, or monitoring of symptoms only. All patients scored asthma symptoms in an electronic diary over 30 weeks; 77 received a portable nitric oxide (NO) analyzer. Data were transmitted daily to the coordinating centers. Patients were phoned every 3 weeks and their steroid dose was adapted according to FENO0.05 and symptoms, or according to symptoms. Children were seen at 3, 12, 21, and 30 weeks for examination and lung function testing. The primary end point was the proportion of symptom-free days in the last 12 study weeks. Measurements and Main Results: Telemonitoring was feasible with reliable FENO0.05 data for 86{\%} of days, and valid diary entries for 79{\%} of days. Both groups showed an increase in symptom-free days, improvement of FEV1 and quality of life, and a reduction in steroid dose. None of the changes from baseline differed between groups. The difference in symptom-free days over the last 12 weekswas0.3{\%} (P = 0.95; 95{\%} confidence interval, -10 to 11{\%}). There was a trend for fewer exacerbations in the FE NO0.05 group. Conclusions: Thirty weeks of daily FENO0.05 and symptom telemonitoring was associated with improved asthma control and a lower steroid dose. We found no added value of daily FENO0.05 monitoring compared with daily symptom monitoring only.",
keywords = "Airway inflammation, Inhaled corticosteroid, Lung function, Symptom-free days, Telemedicine",
author = "{de Jongste}, {Johan C.} and Silvia Carraro and Hop, {Wim C.} and Eugenio Baraldi and Aanstoot, {Henk Jan} and Attillio Boner and {de Benedictis}, {Fernando Maria} and Feith, {Sander W W} and Greijn, {Marquita H.} and Linda Landi and Gianluigi Marseglia and Elio Novembre and Lydia Pescollderung and Giovanni Rossi and Ruud Schornagel and Vaessen-Verberne, {Anja A P H} and {van Veen}, {Leonieke N.}",
year = "2009",
month = "1",
day = "15",
doi = "10.1164/rccm.200807-1010OC",
language = "English",
volume = "179",
pages = "93--97",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society - AJRCCM",
number = "2",

}

TY - JOUR

T1 - Daily telemonitoring of exhaled nitric oxide and symptoms in the treatment of childhood asthma

AU - de Jongste, Johan C.

AU - Carraro, Silvia

AU - Hop, Wim C.

AU - Baraldi, Eugenio

AU - Aanstoot, Henk Jan

AU - Boner, Attillio

AU - de Benedictis, Fernando Maria

AU - Feith, Sander W W

AU - Greijn, Marquita H.

AU - Landi, Linda

AU - Marseglia, Gianluigi

AU - Novembre, Elio

AU - Pescollderung, Lydia

AU - Rossi, Giovanni

AU - Schornagel, Ruud

AU - Vaessen-Verberne, Anja A P H

AU - van Veen, Leonieke N.

PY - 2009/1/15

Y1 - 2009/1/15

N2 - Rationale: Asthma treatment might improve when inhaled steroids are titrated on airway inflammation. Fractional exhaled nitric oxide (FE NO0.05), a marker of eosinophilic airway inflammation, can be measured at home. Objectives: We assessed daily FENO0.05 telemonitoring in the management of childhood asthma. Methods: Children with atopic asthma (n = 151) were randomly assigned to two groups: FE NO0.05 plus symptom monitoring, or monitoring of symptoms only. All patients scored asthma symptoms in an electronic diary over 30 weeks; 77 received a portable nitric oxide (NO) analyzer. Data were transmitted daily to the coordinating centers. Patients were phoned every 3 weeks and their steroid dose was adapted according to FENO0.05 and symptoms, or according to symptoms. Children were seen at 3, 12, 21, and 30 weeks for examination and lung function testing. The primary end point was the proportion of symptom-free days in the last 12 study weeks. Measurements and Main Results: Telemonitoring was feasible with reliable FENO0.05 data for 86% of days, and valid diary entries for 79% of days. Both groups showed an increase in symptom-free days, improvement of FEV1 and quality of life, and a reduction in steroid dose. None of the changes from baseline differed between groups. The difference in symptom-free days over the last 12 weekswas0.3% (P = 0.95; 95% confidence interval, -10 to 11%). There was a trend for fewer exacerbations in the FE NO0.05 group. Conclusions: Thirty weeks of daily FENO0.05 and symptom telemonitoring was associated with improved asthma control and a lower steroid dose. We found no added value of daily FENO0.05 monitoring compared with daily symptom monitoring only.

AB - Rationale: Asthma treatment might improve when inhaled steroids are titrated on airway inflammation. Fractional exhaled nitric oxide (FE NO0.05), a marker of eosinophilic airway inflammation, can be measured at home. Objectives: We assessed daily FENO0.05 telemonitoring in the management of childhood asthma. Methods: Children with atopic asthma (n = 151) were randomly assigned to two groups: FE NO0.05 plus symptom monitoring, or monitoring of symptoms only. All patients scored asthma symptoms in an electronic diary over 30 weeks; 77 received a portable nitric oxide (NO) analyzer. Data were transmitted daily to the coordinating centers. Patients were phoned every 3 weeks and their steroid dose was adapted according to FENO0.05 and symptoms, or according to symptoms. Children were seen at 3, 12, 21, and 30 weeks for examination and lung function testing. The primary end point was the proportion of symptom-free days in the last 12 study weeks. Measurements and Main Results: Telemonitoring was feasible with reliable FENO0.05 data for 86% of days, and valid diary entries for 79% of days. Both groups showed an increase in symptom-free days, improvement of FEV1 and quality of life, and a reduction in steroid dose. None of the changes from baseline differed between groups. The difference in symptom-free days over the last 12 weekswas0.3% (P = 0.95; 95% confidence interval, -10 to 11%). There was a trend for fewer exacerbations in the FE NO0.05 group. Conclusions: Thirty weeks of daily FENO0.05 and symptom telemonitoring was associated with improved asthma control and a lower steroid dose. We found no added value of daily FENO0.05 monitoring compared with daily symptom monitoring only.

KW - Airway inflammation

KW - Inhaled corticosteroid

KW - Lung function

KW - Symptom-free days

KW - Telemedicine

UR - http://www.scopus.com/inward/record.url?scp=58449121138&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58449121138&partnerID=8YFLogxK

U2 - 10.1164/rccm.200807-1010OC

DO - 10.1164/rccm.200807-1010OC

M3 - Article

C2 - 18931330

AN - SCOPUS:58449121138

VL - 179

SP - 93

EP - 97

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 2

ER -